Since their description 30 years ago 1, liposomes (phospholipid bilayer vesicles) have found
widespread use as model membrane systems, and have been extensively investigated for …

Strategies used to enhance liposome-mediated drug delivery in vivo include the
enhancement of stability and circulation time in the bloodstream, targeting to specific tissues …

Association of drugs with carriers such as liposomes has marked effects on both the
pharmacokinetic profiles of the carrier and of the carrier-associated drug. In general …

Liposomes are being increasingly utilized to deliver drugs, enzymes, antisense
oligonucleotides, and genes to various therapeutic targets. Liposome-mediated delivery of …

New lipidic carriers suitable for the sustained drug release in vivo are presented. They
consist of middle sized, compact phospholipid vesicles with one or up to few lipid bilayers …

Sterically stabilized (Stealth®) liposomes, in which the surface of liposomes has been
altered, have been developed through the use of glycolipids (principally …

Liposomes (phospholipid-based vesicles) have been investigated since 1970 as a system
for the delivery or targeting of drugs to specific sites in the body. Because of their structural …

Therapeutic applications of intravenously injected liposomes have been limited by their
rapid clearance from the bloodstream and their uptake by the macrophage cells of the liver …

In the first part, medical applications of liposomes loaded with small molecular weight drugs
is discussed and the use of sterically stabilized liposomes containing doxorubicin in cancer …

The lack of stability in blood and the short blood circulation time of pH‐sensitive liposomes
are major drawbacks for their application in‐vivo. To develop pH‐sensitive, serum‐stable …